The University of Pennsylvania (UPenn) Cancer Research Training Program is designed to identify and train a next generation of outstanding investigators focused on the problem of human malignancies. The Program provides the protected time, resources, educational experience and environment necessary to achieve this goal, as has been demonstrated throughout the past twenty-one consecutive years of funding. Traditionally focused on emerging physician-scientists, the Program has been highly successful in nurturing these young investigators to productive research careers in basic and clinical cancer research. To meet the increasing demands of our shared translational research mission, we now propose to integrate recently graduated PhD scientists into the Program. The 43 faculty preceptors from the Abramson Cancer Center (ACC) at UPenn were selected from across the translational research spectrum to provide a rich group of potential mentors to all trainees. The modified Training Program will leverage the existing strengths that have been successful in training our physician-scientists, and add new training experiences for PhD trainees. An Executive Committee broadly representative of the research experiences available to our trainees will oversee the Program, including recruitment, evaluation and career development.
Significant advancement towards preventing and curing human cancer relies on quality investigators dedicated to translational science. The Cancer Research Training Program strives to recruit and train the next generation of individuals who will lead the field of cancer research.
|Stoeck, Alexander; Lejnine, Serguei; Truong, Andrew et al. (2014) Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov 4:1154-67|
|Garfall, Alfred L; Fraietta, Joseph A; Maus, Marcela V (2014) Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med 17:37-46|
|Garfall, A L; Dougherty, A L; Vogl, D T et al. (2014) Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. Bone Marrow Transplant 49:1439-41|
|Meng, Wenzhao; Jayaraman, Sahana; Zhang, Bochao et al. (2014) Trials and Tribulations with VH Replacement. Front Immunol 5:10|
|Veenstra, Christine M; Epstein, Andrew J; Liao, Kaijun et al. (2014) The effect of care setting in the delivery of high-value colon cancer care. Cancer 120:3237-44|
|Capasso, Mario; Diskin, Sharon; Cimmino, Flora et al. (2014) Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res 74:6913-24|
|Wilson, Melissa A; Zhao, Fengmin; Letrero, Richard et al. (2014) Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 20:3328-37|
|Rader, Julieann; Russell, Mike R; Hart, Lori S et al. (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19:6173-82|
|Schnepp, Robert W; Maris, John M (2013) Targeting MYCN: a good BET for improving neuroblastoma therapy? Cancer Discov 3:255-7|
|Villanueva, Jessie; Infante, Jeffrey R; Krepler, Clemens et al. (2013) Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 4:1090-9|
Showing the most recent 10 out of 38 publications